All News
Our single cell protection buffer, the SingleCellProtectTM
Our single cell protection buffer, the SingleCellProtectTM was used in a recently published Nature Communication paper (doi:10.1038/s41467-017-02628-4) 3-4-2018 Previously we showed that single cells collected
Avidin joined to fourth cystic fibrosis consortium (H2020 TAT-CF) progress meeting in Mallorca (Spain)
Day one was dedicated to the 3rd TAT-CF workshop in which researchers from all partners presented their work within the H2020 project (Novel therapeutic approaches for
Recent Press release announced Hungarian companies can make a breakthrough in combating Alzheimer’s disease
The fruitful collaboration of AVIDIN Ltd. and SONEAS Research Ltd. working in the field of drug development has produced outstanding results from professional and also
Avidin’s chemistry R&D unit divided into new Divisions
Avidin’s chemistry R&D unit responsible for chemical synthesis and development was divided into two Divisions: Medicinal Chemistry Department lead by Iván Kanizsai, PhD and Organic
Avidin participated in cystic fibrosis consortium meeting
Avidin awarded with innovative, European Union grant to promote flexible work schedule
Poster in the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Avidin is presenting a poster in collaboration with Sanders-Brown Center on Aging, University of Kentucky at the AD/PDTM 2017 meeting, the 13th International Conference on
Strategic Changes in the Pipeline
Today Avidin anounced that the company has made extensive recostruction of its projects. The R&D pipeline has changed and become updated accordingly (http://avidinbiotech.com/pipeline/). Q134R, Avidin’s
Approval to a Phase 1 Clinical Study
Approval to Initiate a Phase 1, First–In-Man, Clinical Study for Q134R Soneas Research Ltd. in collaboration with Avidin received approval to initiate a Phase 1,